Key facts
- This page summarizes Patrick O'Brien's Form 4 filing for ARROWHEAD PHARMACEUTICALS, INC. (ARWR).
- 6 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 07 Jan 2022, 19:16.
Patrick O'Brien - 05 Jan 2022 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
- Reporting relationship
- General Counsel
- Issuer ticker
- ARWR
- Reported as of
- 05 Jan 2022
- Net transaction value
- -$2,005,875
- SEC form
- 4
- Accepted by SEC
- 07 Jan 2022, 19:16:18 UTC
- Prior SEC filing
- 04 Jan 2022
- Next SEC filing
- 22 Dec 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Patrick O'Brien
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Patrick O'Brien filed Form 4 for ARROWHEAD PHARMACEUTICALS, INC. (ARWR) on 07 Jan 2022.
Change
- Previous filing in this sequence was filed on 04 Jan 2022.
- Current net transaction value: -$2,005,875.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ARWR
transaction
Common Stock
Sale
- Transaction value
- $752,133
- Shares
- -12,434
- Change %
- -3.3%
- Price
- $60.49
- Shares after
- 368,941
- Date
- 05 Jan 2022
- Ownership
- Direct
- Footnotes
- F1, F2
ARWR
transaction
Common Stock
Sale
- Transaction value
- $640,458
- Shares
- -10,350
- Change %
- -2.8%
- Price
- $61.88
- Shares after
- 358,591
- Date
- 05 Jan 2022
- Ownership
- Direct
- Footnotes
- F1, F3
ARWR
transaction
Common Stock
Sale
- Transaction value
- $312,450
- Shares
- -5,000
- Change %
- -1.4%
- Price
- $62.49
- Shares after
- 353,591
- Date
- 05 Jan 2022
- Ownership
- Direct
- Footnotes
- F1, F4
ARWR
transaction
Common Stock
Sale
- Transaction value
- $280,500
- Shares
- -4,400
- Change %
- -1.2%
- Price
- $63.75
- Shares after
- 349,191
- Date
- 05 Jan 2022
- Ownership
- Direct
- Footnotes
- F1, F5
ARWR
transaction
Common Stock
Sale
- Transaction value
- $20,335
- Shares
- -316
- Change %
- -0.09%
- Price
- $64.35
- Shares after
- 348,875
- Date
- 05 Jan 2022
- Ownership
- Direct
- Footnotes
- F1, F6
ARWR
transaction
Common Stock
Gift
- Transaction value
- $0
- Shares
- -800
- Change %
- -0.23%
- Price
- $0.000000
- Shares after
- 348,075
- Date
- 04 Dec 2020
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.07 to $60.99, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.08 to $62.03, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.09 to $63.02, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Footnote F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.19 to $64.07, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Footnote F6
Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.